1993 - 1997: University of Cape Town, South Africa

On completing his BSc Hons, and MBBCh at the University of the Witwatersrand in 1990, Dr Rabiner trained as a specialist Psychiatrist at the University of Cape Town, gaining his Fellowship of the South African College of Psychiatrists of South Africa (FCPsych SA) in 1996. 

1997 - 2001: MRC Cyclotron Unit, Hammersmith Hospital, London, UK

From 1997 to 2001 Dr Rabiner trained in PET imaging at the MRC Cyclotron Unit, working primarily on characterizing the 5-HT_1A receptor status in healthy individuals and patients with mood and anxiety disorders, as well as utilizing PET to support novel drug development aimed at the 5-HT1A receptor. Dr Rabiner also spent two years (1997-1999) attached to the Psychopharmacology Unit of the University of Oxford.

2001- 2011 GSK Clinical Imaging Centre

In 2001 Dr Rabiner joined the GSK department of Translational Medicine and Genetics, and participated in the establishment of the GSK Clinical Imaging Centre on the Hammersmith Hospital campus in London. Dr Rabiner became the Head of Imaging Applications at the GSK CIC and worked on the development of novel imaging paradigms to support novel drug development and the integration of imaging techniques into the process of drug development.

2011- Present Imanova Ltd.

In 2011 the GSK CIC was spun out as an independent company tasked with serving as the UK national resource for molecular imaging – Imanova Ltd. Imanova Ltd is a joint venture owned by the three major London Universities (ICL, KCL and UCL) and the MRC. Dr Rabiner took the role of Head of Imaging Applications and Chief Medical Officer at Imanova.

2012- Present Institute of Psychiatry, Kings College London.

In 2012 Dr Rabiner was appointed as a Reader in Molecular Neuroimaging at the Centre for Neuroscience Imaging, Institute of Psychiatry, King’s College London. 

Dr Rabiner specializes in the application of molecular imaging to the investigation of neurochemistry and neurophysiology, and in particular in applying molecular imaging techniques to support novel drug development.  His work to date has focused on the investigation of in vivo pharmacology and the optimisation of methods to expedite the drug development process and characterize novel PET radioligands, and in the integration of molecular imaging techniques with functional imaging methods such as BOLD fMRI and ASL. 

Current research projects include the development of imaging techniques to quantify neuroinflammation and to extend the detection of endogenous neurotransmitter release beyond that of dopamine.